McKesson Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up

AI-generated analysis

📉 MCK stock fell 0.4% in after-hours trading despite reporting a Q4 earnings beat, as shares lost 9.7% year-to-date while the broader market rose 8.6%.

💰 Adjusted EPS of $11.69 exceeded analyst consensus by 1.1%, driven largely by a significant pre-tax credit related to the Rite Aid bankruptcy within the North American Pharmaceutical segment.

📊 GAAP EPS reached $13.71, representing a substantial improvement over the prior year's figure of $10.01.

🚀 Full fiscal 2026 adjusted EPS is forecasted to rise 18.3% to $39.11, while GAAP EPS is projected to jump 49.2% to $38.38.

💸 Total revenue of $96.3 billion missed consensus estimates by 5.5%, though the top line still grew 6% year-over-year driven by retail national accounts and oncology growth.

🏥 The Oncology & Multispecialty segment was a standout with revenues surging 31% to $12.71 billion due to acquisitions and growth in provider solutions.

💉 North American Pharmaceutical segment revenue grew 3% to $79.12 billion, partially offset by lower branded pharmaceutical contributions but aided by increased prescription volumes.

🛠️ Prescription Technology Solutions revenues increased 12% to $1.5 billion, driven by higher demand for access and logistics services.

🩹 Medical-Surgical Solutions revenue remained flat at 1% growth ($2.87 billion), with profits up slightly due to cost optimization despite lower ambulatory care channel contributions.

📈 Adjusted operating margin expanded 15 basis points to 2.04%, supported by a 14% increase in adjusted gross profit.

💵 Cash and cash equivalents grew to $3.98 billion, up from $2.96 billion in the previous quarter.

📅 Effective from Q2 of fiscal 2026, the company adopted new reportable segments including North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

🔮 For fiscal 2027, McKesson expects adjusted EPS to grow 12-14% to a range of $43.80-$44.60 with total revenues growing between 5-9%.

🔭 Future guidance specifies North American Pharmaceutical revenue growth of 4-8% and Oncology & Multispecialty revenue growth of 14.5-18.5%.

🤖 The company anticipates flat to +4% operating profit for the Medical-Surgical Solutions segment in fiscal 2027.

🏆 Specialty distribution continued to be a key driver, supported by strong volumes and market share gains in community oncology.

Full Analysis
McKesson Corporation (MCK) reported fourth-quarter fiscal 2026 results on May 7, delivering an adjusted earnings per share (EPS) beat while missing revenue expectations. The company posted adjusted Q4 EPS of $11.69, surpassing the Zacks Consensus Estimate of $11.56 by 1.1%, with GAAP EPS reaching $13.71 due to a one-time pre-tax credit related to Rite Aid's bankruptcy in the North American Pharmaceutical segment. Full-year fiscal 2026 adjusted EPS guidance for fiscal 2027 reflects this improvement, with projected growth of 12-14% to a range of $43.80-$44.60. Despite the earnings beat, Q4 revenues totaled $96.3 billion, falling short of analyst consensus by 5.5%, though this represented a 6% year-over-year increase driven primarily by retail national account customers and growth in oncology and specialty product distribution. The miss was partially attributed to lower contributions from branded pharmaceuticals. Operating margins expanded, with adjusted gross profit reaching $3.86 billion (4.01% of net revenues) and adjusted operating income rising 14.6% to $1.97 billion, driven by operational improvements across all business units. Segment performance highlighted strong growth in the Oncology & Multispecialty division, which saw revenue jump 31% to $12.71 billion, fueled by provider solutions and acquisitions, while North American Pharmaceutical revenues grew 3% to $79.12 billion. Prescription Technology Solutions also contributed with a 12% revenue increase, whereas Medical-Surgical Solutions remained relatively flat at 1% growth. For fiscal 2027, McKesson expects total revenue growth of 5-9% and specific segment guidance ranging from 4% to 18.5% depending on the division, signaling continued confidence in specialty distribution and technology service demand despite the quarterly sales shortfall.